Sonnet BioTherapeutics Holdings Inc is a clinical-stage biopharmaceutical company. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
If you understand the idea,π― press a thumb up! π Have a question? Don't be shy to ask! π€ Interested to study how to analyze charts, follow me!
If you understand the idea,π― press a thumb up! π Have a question? Don't be shy to ask! π€ Interested to study how to analyze charts, follow me!